Antidepressant studies in Parkinson's disease: A review and meta‐analysis
暂无分享,去创建一个
I. Katz | P. Moberg | W. Bilker | M. Stern | D. Weintraub | J. Duda | K. Morales | Catherine C. Balderston
[1] C. Clarke,et al. Systematic review of antidepressant therapies in Parkinson's disease. , 2003, Parkinsonism & related disorders.
[2] Daniel Weintraub,et al. Recognition and Treatment of Depression in Parkinson's Disease , 2003, Journal of geriatric psychiatry and neurology.
[3] K. Krishnan,et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. , 2003, The American journal of psychiatry.
[4] A. Leentjens,et al. SSRIs in the treatment of depression in Parkinson's disease , 2003, International journal of geriatric psychiatry.
[5] J. Marinus,et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. , 2003, The Journal of neuropsychiatry and clinical neurosciences.
[6] R. Roos,et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. , 2002, British journal of clinical pharmacology.
[7] A. Stoessl,et al. The placebo effect in Parkinson's disease , 2002, Trends in Neurosciences.
[8] T. Oxman,et al. Treatment of minor depression. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[9] R. Ackermann,et al. Rational treatment choices for non-major depressions in primary care , 2002, Journal of General Internal Medicine.
[10] M. Lemke,et al. Effect of reboxetine on depression in Parkinson's disease patients. , 2002, The Journal of clinical psychiatry.
[11] S. Chiechio,et al. The SSRI, Citalopram, Improves Bradykinesia in Patients With Parkinson's Disease Treated with L-Dopa , 2002, Clinical neuropharmacology.
[12] I. Katz,et al. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. , 2001, Postgraduate medicine.
[13] G. Dell''Agnello,et al. SSRIs Do Not Worsen Parkinson's Disease: Evidence from an Open-Label, Prospective Study , 2001, Clinical neuropharmacology.
[14] M. Martens,et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.
[15] Alex J. Sutton,et al. Methods for Meta-Analysis in Medical Research , 2000 .
[16] T. Bottiglieri,et al. S‐adenosyl‐methionine improves depression in patients with Parkinson's disease in an open‐label clinical trial , 2000, Movement disorders : official journal of the Movement Disorder Society.
[17] L. Murri,et al. Paroxetine in Parkinson’s disease: Effects on motor and depressive symptoms , 2000, Neurology.
[18] C. Mariani,et al. Tolerability of paroxetine in Parkinson's disease: A prospective study , 2000, Movement disorders : official journal of the Movement Disorder Society.
[19] Z. Rihmer Maria Satori Peter Pestality. Selegiline-citalopram combination in patients with Parkinson's disease and major depression , 2000, International journal of psychiatry in clinical practice.
[20] J. Cummings,et al. Depression in patients with Parkinson's disease , 1999, International journal of geriatric psychiatry.
[21] D. Deeg,et al. Depression in Parkinson's disease. The impact of symptom overlap on prevalence. , 1998, Psychosomatics.
[22] Roger Kurlan,et al. A survey of antidepressant drug use in Parkinson's disease , 1997, Neurology.
[23] R. Hauser,et al. Sertraline for the treatment of depression in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.
[24] J. Cummings,et al. Risk factors for depression in Parkinson disease. , 1997, Archives of neurology.
[25] Robert Rosenthal,et al. Computing Contrasts, Effect Sizes, and Counternulls on Other People's Published Data: General Procedures for Research Consumers , 1996 .
[26] I. Olkin,et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.
[27] J. Cummings,et al. The occurrence of depression in Parkinson's disease. A community-based study. , 1996, Archives of neurology.
[28] G. Tollefson,et al. A Double-Blind, Placebo-Controlled Clinical Trial of Fluoxetine in Geriatric Patients With Major Depression , 1995, International Psychogeriatrics.
[29] T. Chase,et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging , 1992, Neurology.
[30] M. Hietanen. Selegiline and cognitive function in Parkinson's disease , 1991, Acta neurologica Scandinavica.
[31] H. Allain,et al. Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT) , 1991, Acta neurologica Scandinavica. Supplementum.
[32] R G Robinson,et al. Depression in Parkinson's Disease , 1990, The Journal of nervous and mental disease.
[33] P. Carrieri,et al. Amitriptyline in the treatment of headache in patients with Parkinson's disease , 1988, Neurology.
[34] J. Yesavage,et al. Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .
[35] R. Mayeux,et al. Clinical and biochemical features of depression in Parkinson's disease. , 1986, The American journal of psychiatry.
[36] C. Tanner,et al. Bupropion in Parkinson's disease , 1984, Neurology.
[37] Y. Agid,et al. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. , 1983, Journal of affective disorders.
[38] A. Korczyn,et al. DEPRENYL IN PARKINSON'S DISEASE , 1982, The Lancet.
[39] J. Andersen,et al. Anti‐depressive treatment in Parkinson's disease A CONTROLLED TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH L‐DOPA , 1980, Acta neurologica Scandinavica.
[40] M. Åsberg,et al. A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.
[41] C. Marsden,et al. Nomifensine in Parkinson's disease. , 1977, British journal of clinical pharmacology.
[42] G. Glass. 9: Integrating Findings: The Meta-Analysis of Research , 1977 .
[43] L. Laitinen. DESIPRAMINE IN TREATMENT OF PARKINSON'S DISEASE , 1969 .
[44] M. Macculloch,et al. THE APPLICATION OF ANTICIPATORY AVOIDANCE LEARNING TO THE TREATMENT OF HOMOSEXUALITY. I. THEORY, TECHNIQUE AND PRELIMINARY RESULTS. , 1966, Behaviour research and therapy.
[45] R. Strang. Imipramine in Treatment of Parkinsonism: a Double-blind Placebo Study , 1965, British medical journal.
[46] A. Beck,et al. An inventory for measuring depression. , 1961, Archives of general psychiatry.
[47] M. Hamilton. A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.
[48] Juan Carlos Espinosa,et al. Comprehensive Meta-Analysis , 2004 .
[49] A. Desautels,et al. Effects of immobility on sensory and motor symptoms of restless legs syndrome , 2002, Movement disorders : official journal of the Movement Disorder Society.
[50] M. Brin,et al. Treatment of depression in idiopathic Parkinson's disease , 2022 .
[51] P. Bech,et al. a2-Adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson disease and depression , 2000 .
[52] P. Bech,et al. Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson disease: A pilot study , 1999 .
[53] J. En,et al. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. , 1999 .
[54] E. J. Jansen Steur,et al. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. , 1999, Advances in neurology.
[55] P. Bech,et al. Applicability and validity of the Major Depression Inventory in patients with Parkinson's disease , 1998 .
[56] P. Bech,et al. Depression in idiopathic Parkinson's disease treated with citalopram: A placebo-controlled trial , 1998 .
[57] H. C. D. de Vet,et al. Treatment of depression in Parkinson's disease: a meta-analysis. , 1995, The Journal of neuropsychiatry and clinical neurosciences.
[58] E. Troisi,et al. S-adenosylmethionine treatment of depression in patients with Parkinson's disease : a double-blind, crossover study versus placebo , 1990 .
[59] H. Baas,et al. Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. , 1987, Journal of neural transmission. Supplementum.
[60] H. Przuntek,et al. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. , 1987, Journal of neural transmission. Supplementum.
[61] R. Rosenthal. Meta-analytic procedures for social research , 1984 .
[62] J. Feighner,et al. Diagnostic criteria for use in psychiatric research. , 1972, Archives of general psychiatry.
[63] M. Lorr,et al. Profile of mood states , 1971 .
[64] W. Zung. A SELF-RATING DEPRESSION SCALE. , 1965, Archives of general psychiatry.